Akeso, Inc. (9926.HK) (Akeso or the Company) announced that at the 2025 ESMO Asia Congress, updated results from the pivotal ...
IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure ...
In healthcare, the costs are not merely financial. Incomplete, inconsistent or delayed electronic health records can lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback